As previously suggested, it may be feasible to impede tumorevoked angiogenesis with a nutraceutical program composed of glycine, fish oil, epigallocatechin-3-gallate, selenium, and silymarin, complemented by a low-fat vegan diet, exercise training, and, if feasible, a salicylate and the drug tetrathiomolybdate. It is now proposed that the scope of this program be expanded to address additional common needs of cancer patients: blocking the process of metastasis; boosting the cytotoxic capacity of innate immune defenses (natural killer [NK] cells); preventing cachexia, thromboembolism, and tumor-induced osteolysis; and maintaining optimal micronutrient status. Modified citrus pectin, a galectin-3 antagonist, has impressive antimetastatic potential. Mushroom β-glucans and probiotic lactobacilli can amplify NK activity via stimulatory effects on macrophages. Selenium, β-carotene, and glutamine can also increase the number and/or cytotoxic activity of NK cells. Cachectic loss of muscle mass can be opposed by fish oil, glutamine, and β-hydroxy-βmethylbutyrate. Fish oil, policosanol, and vitamin D may have potential for control of osteolysis. High-dose aspirin or salicylates, by preventing NF-κB activation, can be expected to aid prevention of metastasis and cachexia while down-regulating osteolysis, but their impacts on innate immune defenses will not be entirely favorable. A nutritional insurance formula crafted for the special needs of cancer patients can be included in this regimen. To minimize patient inconvenience, this complex core nutraceutical program could be configured as an oil product, a powder, and a capsule product, with the nutritional insurance formula provided in tablets. It would be of interest to test this program in nude mouse xenograft models.
In 2 previous essays, it has been proposed that a comprehensive, carefully targeted program of nutraceutical supplementation, in conjunction with a low-fat, whole-foods vegan diet, regular aerobic exercise, and, optimally, tetrathiomolybdate (TTM) therapy, could be expected to have a worthwhile suppressive impact on tumor-evoked angiogenesis, thereby prolonging survival and, at least in some favorable cases, increasing chances for a curative response to cytotoxic therapies. 1, 2 This proposed program has been given the name multifocal angiostatic therapy to emphasize that it seeks to attack the angiogenic process at multiple points with the intent of achieving complementary or synergistic interactions. The nutraceuticals identified as of likely value in such a program include eicosapentaenoic acid (EPA)-rich fish oil, epigallocatechin-3-gallate (EGCG; in green tea polyphenol extracts), selenium, glycine, and silymarin; diindolylmethane may also have potential in this regard if it proves feasible to achieve plasma concentrations of 5 µM or more with tolerable oral doses. Such a program would entail daily administration of an oil (EPA, in capsules or a flavored emulsion), a powder (glycine), and a capsule formulation.
While suppression of angiogenesis is a clinical goal that should be of benefit to most patients with cancer, there clearly are other goals that would be of value to most cancer patients: these include targeting the metastatic process, boosting anticancer immune defenses, preventing cachexia and thromboembolism, inhibiting tumor-induced osteolysis, and maintaining good micronutrient status. Moreover, a literature review reveals that feasible nutraceutical strategies for addressing these goals may already be at hand. It is therefore proposed that the nutraceutical program suggested for multifocal angiostatic therapy be expanded to encompass these additional goals and that, to optimize patient convenience and compliance, this program once again be configured as an oil, a powder, and a capsule formulation. This proposed program will be referred to as a core nutraceutical program (CNP) for cancer management.
This CNP is intended to be of value to most patients coping with cancer. There can be no pretense that it will constitute the totality of appropriate supplementation for individual patients; evidently, certain nutraceuticals may have tumor-specific utility for directly influencing tumor behavior, amplifying response to concurrent cytotoxic therapy or preventing/ameliorating certain other complications of clinical cancer or cancer therapy. But the CNP can be viewed as a good baseline supplementation strategy, to which additional components can be added as warranted in individual cases.
The remainder of this essay provides a concise overview of nutraceutical strategies that, on the basis of current evidence, appear to have promise as components of CNP.
Preventing Metastasis
There is now evidence that once a cancer cell or cluster of such cells enters the bloodstream, embolization in a capillary bed is not sufficient to enable the cell(s) to extravasate and give rise to a new metastasis; adherence of the cell(s) to endothelium is also required for this to succeed. 3 The lectin galectin-3, expressed on the surface of endothelial cells as well as that of many cancers, appears often to play a prominent role in mediating such adherence. 4 Thus, antibodies or small molecules that prevent galectin-3 from binding to galactose-rich membrane glycoproteins have been shown to substantially reduce the frequency of metastases in animal models of metastasis. 3, [5] [6] [7] [8] The fact that metastases tend to be richer in galectin-3 than primary tumors are likewise suggests a key role for this lectin in the metastatic process. 9, 10 Moreover, there is evidence that galectin-3 (and possibly other galactose-binding lectins) plays a role in capillary tube formation and also protects certain galectin-3-expressing tumors from anoikis, the special type of apoptosis that results when cells are deprived of adequate adhesive connections to other cells or to ground substance. [11] [12] [13] [14] (Anoikis accounts for the fact that most circulating cancer cells die before they can give rise to a metastasis.) Thus, agents that can impede the binding of galectin-3 to its physiological targets may have potential not only for blocking the metastatic process but also for rendering angiogenesis less effective and, in some cases, promoting anoikis-mediated death of cancer cells.
Modified citrus pectin (MCP)-a derivative of citrus pectin prepared by sequential treatment with base and then acid, which converts the pectin to lowermolecular-weight, unbranched, galactose-rich polysaccharides with improved oral absorbability-appears to have great clinical potential as a galectin-3 antagonist. Thus, in 2 rodent studies, oral administration of MCP has been shown to inhibit spontaneous lung or liver metastasis in rodents bearing transplanted tumors. 12, 15 Growth of the primary tumor was also significantly suppressed in 2 studies, an effect at least partially attributable to inhibition of tumor-evoked angiogenesis 12, 16 ; no such effect was noted in another study, however. 15 In vitro, MCP has been shown to dose dependently inhibit the binding of various types of cancer cells to endothelial cells, to likewise inhibit the binding of soluble galectin-3 to endothelial cells, and to inhibit the process of capillary tube formation during in vitro angiogenesis. 12 A published clinical study has examined the impact of MCP (5 g, 3 times daily in capsules) on prostatespecific antigen (PSA) doubling time in men whose blood PSA was still detectible and rising following localized therapy for prostate cancer. 17 This study exploited the observation that in men with early prostate cancer not currently undergoing treatment, log(PSA) tends to rise linearly, implying that tumor doubling time tends to remain constant. 18 Using each patient as his own control, the investigators observed the impact of MCP administration on PSA doubling time in 13 patients, 10 of whom satisfactorily completed the protocol; 7 of these patients achieved a significant reduction of doubling time following the initiation of MCP therapy. In 4 of these cases, the doubling time rose by 3-fold or more. Three of the patients originally enrolled dropped out because of gastrointestinal (GI) side effects: diarrhea or intestinal discomfort, commonly seen when soluble fiber is administered in high doses to individuals acclimated to low-fiber diets. This study constitutes an elegant demonstration that oral MCP may have genuine clinical potential. However, it could not clarify the extent to which suppression of metastasis, inhibition of angiogenesis, or direct effects on tumor cells contributed to the therapeutic response.
In light of the fact that more than a decade has elapsed since MCP was first proposed as a cancer therapy, it is disappointing-though perhaps not surprising, in light of the low potential for pharmaceutical profit-that a more substantial clinical and preclinical literature on MCP is not at hand. MCP is highly soluble, blends readily into water or juice, and its acidic flavor is readily masked. Thus, its inclusion in the powder component of CNP would appear feasible.
Constitutive activation of NF-κB is commonly encountered in advanced cancers, 19 and this transcription factor is also activated in inflamed endothelial cells. NF-κB promotes expression of various adhesion factors-including galectin-3 20,21 -that can aid tumor cell-endothelium adhesion; moreover, NF-κB in cancer cells further aids their metastatic capacity by inducing expression of matrix proteases. [22] [23] [24] [25] [26] [27] [28] It is thus intriguing that both aspirin and salicylate, in the high clinical concentrations that achieve the best benefit in rheumatic disorders, can suppress activation of NF-κB by blocking the kinase activity of its upstream activator IκB kinase-β INTEGRATIVE CANCER THERAPIES 5(2); 2006 (IKK-β); these drugs are competitive inhibitors of adenosine triphosphate binding to IKK-β. 29, 30 This presumably accounts for the antimetastatic activity of aspirin-not shared by indomethacin-reported in a rodent model of metastasis. 31, 32 In vitro, aspirin inhibits the invasive capacity of cancer cells and suppresses adhesion to endothelial cells. 22, 26, [33] [34] [35] [36] For unknown reasons, TTM also inhibits NF-κB activation in some tumors, although the generality of this effect has not yet been established. 37, 38 Potentially, silibinin, the active component of silymarin, can suppress at least some routes of NF-κB activation by an interaction with IκB kinase-α 39 ; the extent to which this effect, documented in vitro, contributes to silymarin's cancer-retardant and angiostatic effects in vivo remains to be clarified. These considerations suggest that high-dose aspirin-or better tolerated sources of salicylate, such as salsalate 40 or enteric-coated sodium salicylate-and possibly TTM and silymarin as well may be able to complement the utility of MCP in impeding the metastatic process.
EGCG, the principal polyphenol of green tea, has antiangiogenic activity likely rooted in inhibition of the kinase activity of vascular endothelial growth factor receptor (VEGFR)-2. 41 But it is also suspected to have antimetastatic activity, inasmuch as in low micromolar concentrations, it can inhibit the matrix metalloproteinases (MMPs) 2 and 9. 42, 43 Whether these effects are significant in vivo is currently unclear since it is hard to sustain plasma EGCG concentrations in excess of 1 µM, owing to rapid hepatic conjugation of this molecule. Furthermore, reports regarding the IC 50 values for these inhibitions are inconsistent. However, one group has reported that submicromolar concentrations of EGCG can inhibit cancer cell invasion of Matrigel in a Boyden chamber. 43 Moreover, there are 2 reports that oral administration of green tea inhibits spontaneous lung metastasis in mice bearing transplanted tumors. 44, 45 Thus, the EGCG component of CNP might make some contribution to metastasis prevention, although, if so, the precise mechanism remains uncertain.
Boosting Immune Defenses: Focus on Natural Killer Cells
The bright hopes originally expressed for immunotherapy of cancer have come to grief on the fact that, with the notable exception of cancers that arise from viral infections that can also infect antigen-presenting cells (APCs), most clinical cancers are poorly immunogenic. 46 This reflects the fact that cancer-specific immunogenic peptides, arising, for example, from oncogenic mutations or renewed expression of fetal proteins, are unlikely to be expressed by APCs in the absence of complex therapeutic manipulations that make such expression possible. Thus, antigen-specific T-cell-mediated scavenging of cancer cells seems to have little impact on the clinical course of most cancer patients. A number of immunotherapeutic strategies for producing antigen-specific cytotoxic T-cell clones that might indeed exert a significant influence on the spread of a targeted tumor are being explored on an experimental basis, but for the time being, such strategies are unavailable to most patients. However, there is growing evidence that antigen-non-specific innate mechanisms, particularly those mediated by natural killer (NK) cells, do indeed have an impact on development and spread of many cancers-particularly with respect to scavenging of small nests of cancer cells, such as tiny incipient cancers or new metastases. 47, 48 NK mechanisms appear to have less impact on large primary tumors, so they are best evoked for prevention of metastasis or for improving the chance of a cure following definitive cytotoxic therapy.
Many viruses have evolved the knack of suppressing host cell expression of major histocompatibility complex (MHC) class 1 molecules, thereby protecting the host cell from attack by antigen-specific cytotoxic T cells. Animals, in turn, have evolved NK cells to seek out and kill cells in which the expression of MHC class 1 is anomalously low; they carry special inhibitory receptors that detect the production of MHC class 1 molecules by cells that are potential targets for their cytotoxic activity. 47 By a happy coincidence, MHC class 1 expression is diminished or absent in a high proportion of cancer cells. 49, 50 The basis of this effect is still unclear; it would clearly represent an adaptive mechanism in cancer cells that are potentially immunogenic, but in fact most cancers are poorly immunogenic. Perhaps the deficit of MHC class 1 in many cancers is an epiphenomenon reflecting some other biological quirk of these cells that is indeed adaptive. In any case, the dearth of MCH class 1 expression in many tumors renders them susceptible to NK attack.
Micronutrient status clearly has an impact on NK function; selenium, β-carotene, and zinc have received particular attention in this regard. In the context of adequate selenium nutrition, increased supplemental intakes of this nutrient boost expression of the interleukin (IL)-2 receptor in activated T cells and NK cells; this can be expected to enhance clonal expansion of stimulated cells and to boost their function. 51, 52 In normally nourished humans, supplementation with 200 to 400 µg selenium daily has been reported to increase both the number of circulating NK cells and their cytotoxic activity; in a long-term study, the impact on NK cell numbers was more durable than the impact on their activity. 53, 54 Similar observations are reported in rodents. 51, 55 Supplemental β-carotene has been found to boost the cytotoxic activity of NK cells, without notably altering their numbers. 54, [56] [57] [58] These effects are seen in rodents and humans; however, elderly humans seem to be more susceptible to this benefit than younger ones are. This observation arose from the Physician's Health Study, in which the subjects randomized to β-carotene received 50 mg every other day; at this dose level, NK cytotoxic activity rose by about a third. 58 This β-carotene supplementation regimen did not influence the production of NK-stimulatory cytokines such as IL-12 or interferons by circulating monocytes, suggesting that β-carotene may have acted directly on NK cells to boost their activity. 59 The molecular basis of this effect remains unknown. With respect to zinc, it is clear that adequate zinc status is necessary for good NK function, [60] [61] [62] but zinc megadoses do not appear to have any durable impact on NK cells, and, in vitro, high concentrations of zinc are inhibitory. [63] [64] [65] Thus, a good CNP should ensure adequate zinc status and provide elevated (but safe) intakes of selenium and β-carotene.
Activated macrophages and dendrites secrete IL-12, and helper T cells (whose activation is contingent of APCs) produce IL-2; each of these cytokines boosts the cytotoxic activity of NK cells for tumors but cannot be produced by NK cells themselves. 47 Thus, agents that promote macrophage activation can be expected to boost NK cytotoxic activity by indirect mechanisms. This is probably the basis of the stimulatory impact of certain complex polysaccharides and of certain probiotic supplements on NK activity. In particular, certain cell wall polysaccharides produced by mushrooms or fungus can interact with receptors expressed on macrophages to activate these cells; these receptors no doubt evolved as part of our innate immune defenses against pathogens that produce polysaccharides not produced by humans. Moreover, although such polysaccharides are typically more effective as immune adjuvants when administered parenterally, some preparations of these agents are sufficiently absorbable to modulate immune mechanisms when fed orally. A number of polysaccharide-rich preparations derived from various types of mushrooms-some of which have long been used in folk medicine-have been studied with respect to their ability to act as orally effective immunostimulants; preparations derived from Agaricus blazei Murr (Agaricaceae; Brazilian sun mushroom), Ganoderma lucidum P Karst (Ganodermataceae; reishi), and Lentinula (Lentinus) edodes (Berk) Pegler (Marasmiaceae; shiitake), among others, have shown potential in this regard. [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] The polysaccharides derived from Agaricus and Ganoderma mycelia-β-Dglucans with 1 → 3 and 1 → 6 linkages-have been shown to activate macrophages via toll-like receptor 4 and CD14 (the receptor system activated by lipopolysaccharides). [79] [80] [81] The oral efficacy of some preparations of these polysaccharides evidently reflects the fact that these are at least partially absorbable despite their high molecular weight (usually in excess of 10 kD).
Preparations derived from A blazei appear to have received the most thorough study in rodent modelsretardation of tumor development and stimulation of NK activity are reported-but this does not necessarily imply that this is the superior source, and headto-head comparisons of these preparations appear not to have been attempted. With respect to clinical trials, there are 2 published studies with Ganoderma. In the first, an uncontrolled trial in patients with advanced cancer who received 1800 mg 3 times daily of a polysaccharide-rich extract, NK levels (CD56+) rose significantly by an average 16%, accompanied by an average increase of 30% in NK cytotoxic activity. 73 In a subsequent study of identical design, targeting patients with advanced lung cancer, no significant effects on any measured immune parameters were noted. 82 Another recent trial examined the impact of an Agaricus preparation (AMBK), administered as 3 packets daily (perplexingly, the intake of polysaccharide that this entailed was not noted), in patients undergoing chemotherapy for gynecological cancers; the design was randomized and placebo controlled. 70 Relative to the placebo group, NK cytotoxic activity rose significantly by about 25% in those receiving AMBK. What perhaps was more intriguing was that the supplementation appeared to have favorable effects on chemotherapy-related side effects such as loss of appetite, alopecia, emotional instability, and general weakness, as quantified by a questionnaire. In the single published clinical trial with Lentinula extract in cancer, use of this treatment was not associated with a lowering of PSA values in any of the 62 patients 83 ; rather than choosing a reduction in PSA as the end point, it would have been more illuminating to look at the impact of therapy on the PSA doubling time, as employed in the MCP study cited above.
While it is impossible to reach a reliable conclusion regarding the relative efficacies of these mushroom extracts in clinical cancer, it is probably fair to conclude that when prepared in an optimal fashion and administered in an adequate dose, such preparations are likely to exert a modestly positive impact on NK function and thus may be worthy of inclusion in a CNP.
Probiotic supplements also have potential as nonspecific immunostimulants. This presumably reflects partial absorbability of their cell-wall polysaccharides and perhaps other cell components capable of activating the innate immune response of macrophages. In both humans and rats, various strains of Lactobacillus and Bifidobacterium, administered in milk or as lyophilized preparations, have been found to boost the cytotoxic activity of NK cells. [84] [85] [86] [87] [88] [89] [90] [91] [92] [93] One of the most illuminating of these studies showed that the Lactobacillus casei Shirota strain, when administered orally to mice injected intradermally with the carcinogen 3-methylcholanthrene, markedly retarded the onset of tumors, accompanied by a notable increase in NK cytotoxicity. When the same experiment was attempted in the beige mouse strain, in which NK function is genetically impaired, the lactobacillus failed to provide such protection. 86 In clinical studies with probiotics, the increases in NK cytotoxic activity have sometimes been quite notable, entailing up to a doubling of this activity; typically, elderly subjects respond more dramatically than younger ones do.
The immunostimulant clinical utility of probiotics appears to be somewhat better documented at this point than that of mushroom preparations. In patients who are attempting a vegan diet to downregulate systemic insulin-like growth factor (IGF)-I activity, it may be preferable to administer such probiotics as lyophilized powders rather than in milk products.
Glutamine is the predominant amino acid in plasma, constituting about half of the amino acid pool. There is a small but intriguing literature demonstrating that increased oral intakes of glutamine, administered at 1 g/kg/d in most studies, markedly slow the growth (by about 40%) of a range of transplanted tumors-a sarcoma, the MTF-7 breast cancer, and Morris hepatoma 7777-in rats while also suppressing the induction of breast cancer with DMBA; the effect on DMBA carcinogenesis was exerted at the promotional stage. [94] [95] [96] [97] These benefits were associated with a marked increase in NK cytotoxicity; it was suspected that this was at least partially responsible for the observed tumor retardation. NK cells, like other lymphocytes, make prominent use of glutamine as an energy substrate and precursor for nucleotides, but whether this explains the observed marked impact on NK cytotoxicity is unclear. (Glutamine is also a preferred energy substrate for many cancers.) The authors note that blood levels of prostaglandin E2 (PGE2), a suppressor of NK activity, were notably lower in the glutamine-fed group. 95 Glutamine may have particular utility as a component of a CNP, for, as noted below, it also has potential for preventing or treating cachexia. Since it is soluble, flavorless, and well tolerated, inclusion of ample doses of glutamine in the powder component of CNP appears warranted.
Prostaglandins have an inhibitory impact on NK and macrophage activity; conversely, cyclooxygenase (cox) inhibitors have a favorable impact on NK activity. 98 In tumors that express cox-2, inhibition of this enzyme tends to down-regulate expression of MHC class 1, suggesting that prostaglandins act to maintain expression of these proteins, thereby shielding the cancer from NK attack. Moreover, cox-2-derived prostaglandins could act directly on nearby NK cells to suppress their cytotoxic activity. 99 Thus, cox-2 expression may represent a mechanism whereby a tumor can evade NK attack, and cox-2 inhibitors may have potential for boosting the innate immune response to a tumor. With respect to high-dose aspirinrecommended previously as a potential adjuvant to multifocal angiostatic therapy-its inhibitory impact on NF-κB activity may act as a countervailing factor. Aspirin does not appear to have a direct influence on NK activity, 100, 101 and its ability to inhibit both isoforms of cox should exert a favorable influence in that regard. On the other hand, activation of NF-κB in macrophages plays an important role in macrophage activation; in particular, NF-κB activity promotes transcription of both IL-12 and IL-15, key factors in the maturation and activation of NK cells. [102] [103] [104] [105] Thus, reduction of macrophage activity may be one respect in which high-dose aspirin therapy-or administration of other salicylates-has an adverse impact on cancer management. The net effect of high-dose aspirin on NK activity in vivo appears not to have been studied; concurrent cox inhibition may in some measure mitigate the impact of aspirin on NF-κB. Any adverse effect of aspirin or salicylates on NK activity needs to be balanced against the potentially positive effects of these agents on the aggressive behavior and responsiveness to chemotherapy of the many cancers in which NF-κB and/or cox are constitutively active (M. F. McCarty, unpublished data, 2005); moreover, NF-κB inhibitors have potential for suppressing tumor-evoked angiogenesis, inhibiting metastasis, and-as we shall seepreventing cachexia. 19 Such inhibitors may also decrease the elevated risk for venous thromboembolism associated with cancer 106 ; this risk may reflect increased tumor expression of tissue factor (TF), 107 which is NF-κB inducible. 108 Thus, the net effect of high-dose salicylates seems likely to be positive in most cancer patients, provided that GI toxicity is avoided by appropriate countermeasures (eg, misoprostol) when aspirin is used.
It can be anticipated that, sooner or later, advances in immunotechnology will make it feasible to employ antigen-specific cytotoxic T cells in the management of a significant fraction of cancers, particularly those that are resistant to NK attack owing to ample MHC class 1 expression. It is thus encouraging to note that macrophage stimulants such as β-glucans and probiotics, as well as selenium, can be expected to have a favorable impact on the efficacy of this strategy 53, 69, [109] [110] [111] [112] [113] [114] [115] ; glutamine appears to have received little study in this regard.
Preventing Cachexia
Like osteoporosis, cachexia is a disease that is better prevented than treated. Furthermore, its prevention is vital, as cachexia is considered the proximal cause of death in more than 20% of patients who die of cancer. 116 Thanks to recent studies, in which Tisdale's group has played a particularly prominent role, we are now developing a better understanding of the molecular biology underlying tumor-induced cachexia, which gives us hope of preventing or at least blunting the impact of this disorder with rationally targeted strategies.
Although the cachectic syndrome usually entails some measure of anorexia, this is not primarily responsible for the tissue wasting. 117 The loss of tissue protein seen in cachexia is largely confined to skeletal muscle and reflects the operation of a specific inflammatory syndrome in muscle fibers entailing activation of NF-κB. [118] [119] [120] This activation appears to be necessary and sufficient for increased muscle expression of proteins that mediate the ubiquitin-proteasome-dependent proteolysis pathway and that target myofibrillar proteins for degradation. 119, 121 Cachexia is also typically associated with a marked reduction in fat stores, reflecting an increase in lipolysis provoked by cytokines, but this has a less life-threatening impact than severe loss of muscle mass. 117 Humoral agents secreted by tumors and/or certain proinflammatory cytokines produced by immune cells are responsible for provoking muscle NF-κB activation in neoplastic cachexia. Many of the severest cases of cachexia stem from tumor secretion of proteolysisinducing factor (PIF). [122] [123] [124] [125] [126] The mechanisms by which PIF activates NF-κB are still somewhat obscure but are gradually being clarified. PIF presumably interacts with a receptor that activates phospholipase-A2 activity, liberating arachidonic acid from the plasma membrane. A portion of this is converted to 15(S)-HETE by 15-lipoxygenase; 15-HETE production is necessary and sufficient for NF-κB activation. 127, 128 15-HETE triggers activation of phospholipase C and consequent activity of protein kinase C (PKC) via diacylglycerol; it seems likely that 15-HETE's impact on phospholipase C is mediated by a membrane receptor. PKC activation is also critical for PIF-triggered activation of NF-κB, though whether it is sufficient for this activation is not clear. 128, 129 It now is well known that diets high in EPA-rich fish oil can have a favorable impact on cancer cachexia, both in tumor-bearing rodents and in human patients. Tisdale has examined the impact of EPA on PIFstimulated murine myotubes in vitro. Preincubation with EPA inhibits the impact of PIF both proximally and distally to the production of 15-HETE; not unlikely, EPA can act as a functional antagonist of arachidonic acid in 15-HETE synthesis. 127, 130 However, EPA also inhibits the proteolysis triggered by addition of 15-HETE to these myotubes. The anticatabolic agent β-hydroxyβ-methylbutyrate (HMB; a leucine metabolite found to have a poorly understood favorable impact on the muscle mass and strength of individuals engaged in exercise training [131] [132] [133] ) also suppressed proteolysis in this model; its impact was distal to 15-HETE but proximal to PKC activation. 130 In mice bearing the MAC16 colonic adenocarcinoma, a prolific source of PIF, doses of HMB in excess of 0.125 g/kg/d inhibited the loss of muscle mass. 134 This effect reflected not only a decrease in proteolysis associated with decreased proteasome expression but also a modest increase in protein synthesis. Although no clinical trial to date has evaluated the impact of HMB alone on cancer cachexia, favorable effects have been noted with more complex regimens that include it, as cited below.
EPA supplementation is also protective for MAC16mediated cachexia, although it does not influence protein synthesis 135, 136 ; importantly, docosahexaenoic acid (DHA) does not provide benefit in this regard. EPA has also shown anticachectic efficacy with a rat fibrosarcoma. 137 The clinical literature regarding the utility of fish oil supplementation in cancer cachexia is inconsistent; some studies demonstrate benefit, 138-140 whereas others do not. 141, 142 The most substantial of the positive studies evaluated an EPA intake of 6 g daily. 140 An important consideration not often addressed in these studies is that the ratio of EPA intake to total fat intake might be expected to have an impact on efficacy, as this would be expected to influence the concentration of EPA achieved within cell membranes. Using EPA within the context of a very-low-fat vegan diet would seem likely to optimize its efficacy; however, no studies have yet examined this possibility. Furthermore, it should be recognized that it may take at least several months of supplementation to achieve plateau membrane concentrations of EPA during prolonged administration; this argues for giving EPA as a preventive agent, rather than waiting until cachexia becomes a clinically important issue.
An understanding of PIF's mechanism of action in triggering muscle proteolysis enables us to predict additional strategies that may counteract cachexia. Since NF-κB activation is crucial in this process, highdose salicylates may have potential for prevention of cachexia. Indeed, working with a transgenic mouse model of cachexia in which the mice expressed a constitutively active form of IKK-β, Shoelsen and colleagues showed that salicylate (which inhibited this variant form of the enzyme), administered in ample doses, could largely prevent loss of muscle mass in these mice. 121 Of course, this observation was virtually INTEGRATIVE CANCER THERAPIES 5(2); 2006 tautological: it would have been much more meaningful to test salicylate in a tumor-induced form of cachexia. There is, however, one Italian report, more than a decade old, in which aspirin administration was shown to partially counteract loss of muscle mass in rats bearing the Yoshida AH-130 ascites hepatoma; the dose used in this study appeared to be suboptimal for inhibition of IKK-β, so perhaps a more profound effect would have been seen with a higher dose. 143 The possible utility of high-dose aspirin in cachexia prevention is of particular interest in light of the fact that this drug, via joint inhibition of NF-κB and both cox isoforms, may have potential for inhibiting the malignant behavior of many cancers while increasing their apoptotic responsiveness to cytotoxic therapy and slowing angiogenesis. 144 The possibility that silymarin and TTM might also influence cachexia via NF-κB modulation is worthy of consideration, although it is unclear whether these agents affect NF-κB in skeletal muscle.
Since 15-lipoxygenase activity plays a crucial role in PIF-mediated cachexia, it is intriguing to note that the flavonoid luteolin has been reported to inhibit this enzyme rather potently with an IC 50 of 0.6 µM. 145 Low micromolar concentrations of luteolin can be achieved in mouse plasma following oral administration, albeit there is a rapid fall off in concentration presumably owing to rapid hepatic conjugation of this agent. 146 It seems within the realm of possibility, however, that frequent administration of high doses of luteolin could achieve a meaningful systemic inhibition of 15-lipoxygenase. In the range of 1 to 5 µM, luteolin is also reported to inhibit proliferation of certain cancer cell lines and oppose VEGF-mediated angiogenesis. 147, 148 Evaluation of high-dose oral luteolin in rodent cancer models-particularly those entailing cachexia-may be warranted.
As hinted above, high intakes of glutamine can exert an anticatabolic effect on skeletal muscle in various catabolic disorders, including trauma and cancer cachexia; no such effect is seen in healthy subjects. [149] [150] [151] [152] Several recent clinical trials have examined the impact of supplemental glutamine (14 g daily), in conjunction with arginine (14 g daily, a glutamine precursor) and HMB (3 g daily) in wasting disorders, including cancer. [153] [154] [155] In the cancer study, patients experiencing weight loss were randomized to receive, on a double-blind basis, either this supplementation program or an isonitrogenous blend of nonessential amino acids. 154 Over the first 4 weeks, the patients receiving the active supplementation gained an average of 1.12 kg of lean mass, as opposed to a loss of 1.34 kg lean mass in the control group; this differential was maintained over the remaining 20 weeks of the study. Since arginine is thought to function as a glutamine precursor in this context, it is conceivable that the combination of HMB and a higher dose of glutamine would have provided a comparable benefit.
A potential ancillary benefit of supplemental glutamine in cancer patients is worthy of note: since glutamine is a primary fuel for the GI mucosa, it may have a favorable impact on the GI toxicity associated with various cytotoxic therapies. Thus, Yoshida and colleagues demonstrated that supplemental glutamine (10 g 3 times daily) helped to maintain the functional integrity of the GI tract (assessed by phenolsulfonphthalein absorption) in patients with esophageal cancer receiving radiochemotherapy. 152 Systemic IGF-I and insulin exert an anabolic effect on skeletal muscle and other tissues, primarily owing to an increase in the rate of protein synthesis mediated by mammalian target of rapamycin signaling; however, they also diminish proteolysis a bit by down-regulating some of the muscle-specific ubiquitin ligases that are up-regulated by NF-κB, thereby slowing the muscle proteolysis associated with cancer cachexia. [156] [157] [158] It is clear that measures that boost plasma levels of free IGF-I and of insulin, such as diets rich in calories and high-quality protein and growth hormone injections, can counteract loss of muscle protein in cachexia to some degree. 159 Conversely, the inanition that often accompanies the cachexia syndrome can exacerbate the inflammationinduced loss of muscle protein through its effects on IGF-I/insulin. No doubt, maintaining a reasonably adequate daily intake of calories and protein is crucial for patients threatened with cachexia, although such a strategy will not in itself prevent cachexia in susceptible patients; adequate calorie/protein intake plus measures that address the inflammatory syndrome are required for prevention/reversal of muscle mass loss.
However, IGF-I and/or insulin act as growth factors for a high proportion of tumors and act, directly or indirectly, to promote tumor-evoked angiogenesis. [159] [160] [161] [162] [163] [164] [165] [166] [167] The key value of a low-fat vegan diet of modest protein content, especially when coupled with aerobic exercise training and appropriate loss of excess fat, is that these measures can achieve a moderate down-regulation of plasma levels of insulin and free IGF-I that should frequently be beneficial from the standpoint of cancer control. [168] [169] [170] [171] [172] (Note, for example, the growing evidence that insulin levels are prognostic of clinical course in several common cancers, most notably breast cancer. 167, 173 ) However, such a down-regulation would also be expected to at least modestly exacerbate loss of muscle mass in patients experiencing cachexia. (The fact that in cross-sectional studies, vegans invariably have a lower average body mass index than ovo-lacto-vegetarians or omnivores do 174, 175 may reflect more than just their characteristic leanness; there probably are not any vegan NFL linebackers!) For this reason, the sort of nutraceutical countermeasures suggested above may be of particular value for cancer patients attempting a vegan diet. The particular merit of these measures is that there is no reason to believe that they will raise systemic insulin/IGF-I levels, and in rodent studies, these measures have indeed often been associated with slowed tumor growth. In contrast, increasing the calorie and protein intakes of patients who are experiencing cachectic muscle wasting despite maintaining usual intakes of calories and protein could often prove counterproductive by boosting the capacity of the tumor to proliferate and spread; such measures are warranted only when protein/calorie intakes have been unacceptably low.
In this regard, inclusion of a daily soy protein supplement in Ornish et al's 176 ongoing prostate cancer study may have been a tactical error, as such supplementation has been reported to raise IGF-I levels. [177] [178] [179] If indeed soy isoflavones do have a favorable impact on clinical prostate cancer, they can readily be provided as isolated isoflavones in supplement form.
Preventing Thromboembolism
Cancer patients are at high risk for venous thromboembolism; like cachexia, it is one of the most common proximal causes of death in these patients. 180 This risk appears to increase during treatment with antiangiogenic agents, especially in the context of concurrent chemotherapy [181] [182] [183] ; thus, prevention of thromboembolism may take on increased importance as angiostatic strategies are more fully integrated into cancer management. Although low-molecular-weight heparin has well-documented utility for thromboembolism prevention in cancer patients, 184, 185 with greater efficacy and lower risk for bleeding problems than with oral anticoagulants, it is not practical to put all cancer patients on heparin indefinitely. It is clearly desirable to find safe, orally administrable agents that can decrease thromboembolism risk, particularly for patients not currently using heparin.
Although the pathogenesis of cancer-associated venous thromboembolism is not well understood, it seems likely that the high expression of TF in many cancers plays a key role in this regard (M. F. McCarty, unpublished data, 2006). [186] [187] [188] TF triggers the extrinsic coagulation pathway when it binds to factor VII in the context of a membrane rich in phosphatidylserine. Cancer cells give rise to TF-bearing microparticles that potentially can enter the circulation and bind to activated venular endothelium via P-selectin (M. F. McCarty, unpublished data, 2006) . 184, 189, 190 Microparticles derived from apoptotic cancer cells may be highly procoagulant, as apoptosis induces phosphatidylserine in the inner membrane leaflet to "flip" to the external membrane leaflet, where it can support TF activity. 191 Thromboembolism is not the only potential adverse consequence of tumor TF expression: the thrombin derived from TF activity is a potent angiogenic agent, both because it directly stimulates endothelial cells via protease-activated receptors and because the fibrin deposition it triggers forms a favorable extracellular matrix for the angiogenic process. [192] [193] [194] [195] Furthermore, thrombin acts as an autocrine growth factor for some cancers. 196 These considerations may explain why lowmolecular-weight heparin therapy has been found to increase survival in cancer patients, independent of its impact on thrombosis. 184, 185, 197 Clearly, suppressing tumor expression of TF should be a key goal in cancer therapy.
AP-1, egr-1, and NF-κB promote transcription of the TF gene [198] [199] [200] ; it follows that mitogen-activated protein (MAP) kinase (Erk1/2) and NF-κB activation play a key role in TF induction. As noted above, salicylate, silymarin, and tetrathiomolybdate have potential for blocking NF-κB activation in cancers. With respect to MAP kinase activation, the prudent lifestyle measures recommended above, which down-regulate plasma levels of insulin and free IGF-I, should help to blunt this in some tumors. Drugs that target tyrosine kinase receptors that are overexpressed or constitutively active in some tumors should also be beneficial in this regard.
The increased risk for thromboembolism associated with antiangiogenic therapy may reflect the fact that, in many tissues, hypoxia activates MAP kinase by stimulating PKC activity (M. F. McCarty, unpublished data, 2006) . [201] [202] [203] This phenomenon is unrelated to HIF-1 and appears to reflect phospholipase C activation; how such activation occurs is unclear. It will be of interest to determine whether drugs that selectively inhibit PKCβ-currently being developed as antiangiogenic agents and for prevention of diabetic complications 204,205 -will be able to suppress hypoxic induction of TF in some tumors.
The fact that low-dose aspirin reduces postsurgical risk for venous thromboembolism in the general population 206 suggests that platelet stabilization may aid thromboembolism prevention in cancer patients. Ample intakes of fish oil have a platelet-stabilizing impact that is complementary to that of low-dose aspirin, 207 and taurine may have some utility in this regard as well. 208, 209 Measures that amplify the fibrinolytic response to coagulation may reduce risk for venous thromboembolism. The protease nattokinase, produced by Bacillus subtilis and found in the traditional soyfood natto, has shown fibrinolytic activity even when administered orally. [210] [211] [212] [213] In one recent clinical study, preadministration of 150 mg nattokinase was found to reduce the risk of (asymptomatic) venous thrombosis in airline travelers by about 50%. 213 While nattokinase can cleave fibrin, it seems to have a greater capacity to cleave (and inactivate) plasminogen activation inhibitor-1, the key physiological antagonist of fibrinolysis 214 ; whether this effect is primarily responsible for nattokinase's activity in vivo is not yet clear.
Lifestyle measures that promote good insulin sensitivity, independent of their impact on tumor TF expression, may diminish thromboembolic risk for other reasons. Plasma TF is increased in insulin-resistant subjects who do not have cancer [215] [216] [217] ; this may reflect increased TF production by monocytes. Furthermore, insulin resistance syndrome is associated with increased plasma levels of other procoagulant and antifibrinolytic proteins (eg, factor VII, fibrinogen, plasminogen activator inhibitor-1). 218, 219 Thus, insulin resistance is attended by increased thromboembolic risk in the absence of cancer and most likely would exacerbate this risk in cancer patients.
In summary, the nutraceuticals silymarin, fish oil, policosanol, and nattokinase; the prudent lifestyle recommended with this program; and the drugs salicylate and tetrathiomolybdate appear likely to diminish thromboembolism risk in cancer patients. Low-dose aspirin may be recommended for cancer patients who are not thrombocytopenic.
Slowing Osteolysis
The rate of osteolysis increases in many cancer patients. This can represent a systemic effect-seen with cancers that generate sufficiently large amounts of parathyroid hormone-related protein (PTHrP) to produce physiologically significant plasma levels of this hormone-or a local effect, reflecting osteolysis in the immediate neighborhood of bone metastases that produce PTHrP and/or other osteolytic hormones. 220 Osteolysis promotes the growth of bone metastases, which can induce severe bone pain and give rise to fractures. Hypercalcemia may develop, owing either to the impact of numerous osteolytic metastases or the systemic impact of raised plasma PTHrP; it is said that this complication arises eventually in up to 30% of cancer patients. 221 PTHrP, like its close relative PTH, promotes osteolysis by stimulating PTH receptors on osteoblasts; this stimulation boosts osteoblast production of the ligand for the osteocyte RANK receptor (RANKL) while suppressing production of the soluble decoy receptor for this ligand, osteoprogerin. 220 Activation of the RANK receptor via RANKL promotes the maturation and osteolytic activity of osteocytes via a signal transduction pathway dependent on NF-κB activation. [222] [223] [224] [225] Measures that slow osteolysis would not be expected to prevent the development of bone micrometastases, 220 but they have the potential to slow the growth of osteolytic metastases while preventing or postponing the complications of bone pain, fracture, and hypercalcemia. Evidently, there are 2 logical strategies for addressing the problem of excessive osteolysis: suppressing tumor production of PTHrP and intervening in the signaling pathway that links PTHrP activity to osteolysis.
Three separate promoters regulate transcription of PTHrP. The third of these plays an important role in many tumors and responds to ets1/2 (the activities of which are increased by certain isoforms of PKC) and to Smad3 activated via transforming growth factor (TGF)-β receptors. [226] [227] [228] [229] [230] Osteolysis of bone matrix causes release of bound TGF-β, which can then act on nearby cancer cells to boost their production of PTHrP; this represents an important feed-forward mechanism that sustains osteolysis in bone metastases. 231 However, suppressing TGF-β signaling may not be a good option, as this hormone also exerts antiosteolytic effects on osteoblasts. 232 An alternative possibility arises from the fact that one of the PTHrP promoters features a negative vitamin D response element, such that calcitriol or less calcemic analogs thereof inhibit PTHrP transcription and expression in certain cancer cells. [233] [234] [235] While it would not be appropriate to administer calcitriol to patients harboring PTHrP-expressing tumors (who are already at increased risk for hypercalcemia), less calcemic analogs of calcitriol may prove clinically useful for controlling PTHrP overproduction and thus blunting osteolysis. Theoretically, vitamin D per se might be useful for this purpose in those cancers that express 1α-hydroxylase activity as well as calcitriol receptors.
(Administration of vitamin D may be safe even when plasma levels of PTHrP are high since PTHrP appears to be far less effective than PTH for stimulating renal 1α-hydroxylase activity; calcitriol levels typically are low in humoral hypercalcemia syndrome. 220 ) Since PTHrP can exert intacrine effects that promote the growth, survival, and spread of cancers, [236] [237] [238] [239] controlling PTHrP production may aid cancer control independent of any worthwhile effects on osteolysis.
Quite aside from any impact on tumor production of PTHrP, supplemental vitamin D would be expected to decrease plasma levels of PTH, thereby inhibiting background osteolysis.
As noted, activation of NF-κB is crucial to the signal whereby RANK-RANKL interaction triggers osteolysis by osteocytes. This activation is mediated by IκB kinase-β activation 222, 225 and thus should be susceptible to inhibition by salicylate or aspirin. Indeed, there are several reports that salicylate can exert antiosteolytic effects, both in vitro and in vivo. [240] [241] [242] It does not appear that salicylate's impact on animal models of bone metastasis has been assessed; there is one report that aspirin inhibits osteolysis induced by a human mammary carcinoma, but it is not clear whether cox inhibition might have contributed to this effect. 243 However, administration of a single dose of choline magnesium trisalicylate (1500 mg) was found to provide rapid relief from bone pain associated with metastatic cancer in one double-blind clinical study. 244 Whether tetrathiomolybdate, which inhibits NF-κB activation in certain cancer cells, might have a similar impact on osteocytes has not been studied.
Statins, policosanol, and omega-3-rich fish oil have antiosteolytic effects in ovariectomized rodents. [245] [246] [247] [248] [249] [250] Whether these effects are entirely specific to estrogen deprivation or might also be useful for controlling tumor-induced osteolysis remains to be seen. Although findings are not entirely consistent, epidemiology has linked statin use as well as good omega-3 nutrition with reduced risk for fractures and/or increased bone density. [251] [252] [253] [254] [255] The impact of statins in this regard may reflect inhibition of isoprenylation, in light of the fact that the antiosteolytic activity of aminobisphosphonates has been traced to decreased production of isoprenylpyrophosphates. 256 In vitro, both EPA and DHA have been found to blunt the ability of RANKL to promote NF-κB activation in bone marrow-derived macrophages. 248 Although bisphosphonates are an important clinical tool for managing pain induced by bone metastases, 220 it would seem sensible to take a proactive approach to tumor-induced osteolysis by including well-tolerated antiosteolytic agents in the standard management of cancer patients. A CNP that includes fish oil, vitamin D, and possibly policosanol, complemented by salicylate administration, might well be of use in this regard. Less calcemic analogs of calcitriol that can be administered orally may also find a role in control of tumor-induced osteolysis, once these become available for clinical use.
Ensuring Good Micronutrient Status
Another reasonable goal for a CNP is to ensure that patients maintain good micronutrient status. This may be especially important for patients in whom cancer has had an adverse impact on their appetite or their ability to eat, but it arguably is a good policy for anyone who is not confident that their daily meals are optimally nutritious and varied. For those adopting a vegan diet, vitamin B12 supplementation is crucial, and supplemental vitamin D, calcium, and selenium may also be advisable. 257 Moreover, increased intakes of certain essential or quasi-essential nutrients, including possibly selenium, 258, 259 folic acid, 260, 261 vitamin C, 262 vitamin D, 263, 264 γ-tocopherol, 265 vitamin K, 266, 267 calcium, 268 magnesium, [269] [270] [271] chromium, 272 and lutein, 273, 274 may have a favorable impact on long-term health by diminishing risk for certain common disorders. Inclusion of a welldesigned nutritional insurance formula 275 (more prosaically described as a vitamin/mineral supplement) as a component of a CNP thus seems most reasonable. However, such a formulation should be developed with the special needs of cancer patients in mind.
One key consideration is that for patients who are using TTM as part of an antiangiogenesis strategy, 276, 277 a copper-free insurance formula is mandatory. This may be an important consideration as TTM therapy may currently be the most effective means available for suppressing tumor-evoked angiogenesis; clinical studies currently in progress should give us better insight in this regard.
Limited evidence suggests that high intakes of either thiamine or folic acid may increase the rate of proliferation of certain tumors that have an inherent potential for rapid growth. [278] [279] [280] Presumably, the rate of nucleotide synthesis can become rate limiting for progression through the cell cycle in certain fast-growing tumors, and thiamine or folic acid status, in turn, can regulate the rate of nucleotide production. (Thiamine's influence is mediated by transketolase activity.) On the other hand, a patient's overall metabolic health may not be well served by mediocre intakes of either thiamine or folate, and good folate status may play a role in warding off vascular disease, a potentially important consideration for many elderly cancer patients. 261 In the absence of cogent evidence that minimizing dietary intakes of either of these vitamins has a positive impact on the clinical course of cancer patients, the current prudent course may be to include modest, adequate doses of these vitamins in a CNP insurance formula but to avoid megadoses.
Many epithelia that are cancer prone are now known to express 1α-hydroxylase activity, which converts 25-hydroxyvitamin D to its active form calcitriol. [281] [282] [283] Moreover, these epithelia also typically express vitamin D receptors that, when activated, exert a range of antiproliferative, proapoptotic effects. [284] [285] [286] [287] This may explain why a growing epidemiological literature suggests that good vitamin D status, arising from regular ultraviolet (UV) exposure and/or relatively high dietary intakes of this vitamin, is associated with reduced risk for a wide range of cancers. 288, 289 Moreover, it is now clear that some, though not all, of the cancers that arise from these epithelia continue to express both 1α-hydroxylase and the vitamin D receptor; thus, it may be feasible to beneficially modify the behavior of these cancers through vitamin D supplementation. [281] [282] [283] 290 There is certainly no doubt that calcitriol, or its less calcemic synthetic analogs, can suppress the growth and spread in nude mice of many human tumors that express the vitamin D receptor [291] [292] [293] ; such tumors, which likewise express 1α-hydroxylase activity, may be susceptible to supplemental vitamin D as well. Moreover, activated macrophages that infiltrate tumors may serve as a paracrine source of calcitriol when vitamin D is supplemented. 294 Recently, Vieth and colleagues reported that when vitamin D (2000 IU daily) was administered to 15 prostate cancer patients in whom local therapy had failed (PSA measurable and rising), the PSA doubling time increased from 14.3 months to 25 months, decreasing at least slightly in 14 of the 15 subjects; 9 of the 15 patients experienced no rise in PSA, or a small decline, for months following initiation of vitamin D supplementation. 295 In addition, very recent epidemiology suggests that vitamin D status at the time of initial diagnosis may have a significant impact on cancer prognosis, suggesting that good vitamin D status during initial therapy may have a notable impact on the success of this therapy. [296] [297] [298] Thus, although the relevant evidence is still fragmentary, it seems prudent to ensure that patients maintain good vitamin D status with a daily dose of this vitamin that is of real physiological significance, perhaps 2000 to 4000 IU daily. (The complete safety of 4000 IU has been demonstrated. 299, 300 ) A proviso is that vitamin D may tend to influence macrophage function in a way that reduces the ability of these cells to activate NK and helper T cells. 301, 302 Indeed, this phenomenon may explain the apparent favorable impact of good vitamin D status on risk for certain autoimmune disorders such as multiple sclerosis and type 1 diabetes. (However, there is also some precisely contrary evidence in patients with head and neck cancer: supplementation with high doses of 25-hydroxyvitamin D was reported to increase plasma levels of IL-12 [a major stimulant of NK activity] and interferon-γ, apparently owing to an induced decrease in a suppressor cell population that is characteristically elevated in this disorder 303 ; whether this effect has relevance to other cancers remains to be seen.) There is a theoretical possibility that, in certain cancers that are resistant to vitamin D but susceptible to NK attack, increased vitamin D status might have a detrimental effect. At present, though, the admittedly thin balance of evidence suggests that vitamin D is more likely to help than hurt. In any case, supplemental vitamin D will do no more harm than would regular exposure to UV-rich sunlight.
Adequate intakes of certain organic forms of chromium, notably chromium picolinate, may have the potential to down-regulate plasma insulin levels owing to favorable effects on muscle insulin sensitivity, possibly coupled with increased hepatic capacity for insulin clearance. 272, 304 Lower insulin levels, in turn, would be expected to down-regulate plasma levels of free IGF-I. 172, 305 As noted, IGF-I, and sometimes insulin as well, have growth factor activity for many tumors, and IGF-I also contributes to the angiogenic process. Nonetheless, the net effect of bioactive chromium on intracellular IGF-I or insulin signaling in tumors has not yet been explored, so the net effect of supplemental chromium on IGF-I/insulin activity in tumors is not yet clear. Of potential interest in this regard is a study that observed that lifelong administration of chromium picolinate (1 ppm Cr in the diet) to rats was associated with a 25% increase in maximum lifespan and that all of the rats in the control group had died-primarily from tumors-before any of the rats in the Cr picolinate group had. 306 Downregulation of systemic IGF-I activity might explain this finding since IGF-I appears to act as a pace setter in rodent aging. 307, 308 Until this remarkable observation is replicated, it should be viewed circumspectly, but in the absence of other relevant evidence, it seems reasonable to conclude that inclusion of a physiologically significant dose of Cr picolinate in a CNP insurance formula is warranted at the present time.
In cross-sectional studies, comparatively poor magnesium status (low dietary intakes and/or tissue levels) tends to associate with increased serum insulin and impaired insulin sensitivity. [309] [310] [311] There is also limited evidence that ample supplemental magnesium can favorably influence insulin sensitivity in individuals with below-average tissue levels. 312, 313 Thus, supplemental magnesium might be expected to down-regulate insulin levels in a subset of cancer patients. There appears to be little available evidence regarding the impact of supplemental magnesium on the clinical course in cancer. The reduced risk for colorectal cancer associated with good magnesium nutrition 314 might reflect the impact of magnesium on insulin sensitivity. 315 Current evidence suggests that even in relatively modest daily doses (eg, 200 µg daily), supplemental selenium may reduce the risk for certain common cancers. 258 Whether such supplementation will also prove to have some utility in cancer management, especially in an early stage of cancer, is an intriguing possibility that remains to be evaluated. The favorable impact of nutritional selenium on NK and helper T cell expansion and activity has been noted above. Furthermore, there is limited evidence that increased selenium intakes may exert an antiangiogenic impact by diminishing tumor production of VEGF 316, 317 ; for this reason, selenium has been recommended for the multifocal angiostatic therapy cited above. Of particular interest are recent reports that in mice bearing human tumor xenografts, preadministration of relatively high yet tolerable intakes of selenium can greatly potentiate response to subsequent cytotoxic therapy-likely owing to up-regulation of apoptotic mechanisms-while actually diminishing the systemic toxicity of the therapy. [318] [319] [320] [321] Clinical evaluation of this strategy is now under way. However, the doses of selenium that optimally evoke this effect are likely to border on the toxic range (2000 µg daily is being used in current clinical trials) and thus may be appropriate only for temporary use prior to and during chemotherapy sessions. For the purposes of CNP supplementation, a daily dose of 400 µg selenium would be clearly nontoxic but physiologically meaningful.
Lycopene is another antioxidant nutrient that has attracted attention as possibly anticarcinogenic, particularly with respect to prostate cancer. 322 In vitro, lycopene down-regulates the IGF-I activity of the MCF7 mammary tumor cells by reducing expression of the IGF-I receptor. 323 In vivo, lycopene reduces IGF-I activity in the lung epithelium of ferrets, this time by up-regulating IGFBP-3 expression. 324 Whether lycopene will prove to have more general activity as a modulator of IGF-I activity in vivo remains to be seen, but including this phytonutrient in a CNP insurance formula seems reasonable in light of what is currently known.
The platelets of vegetarians tend to be more aggregable than those of omnivores, 325 and this may reflect the fact that vegetarians have relatively poor taurine status 326, 327 ; platelets are high in taurine, which functions physiologically to restrain platelet aggregation. 208, 209 Since cancer patients are highly prone to thrombotic complications, 106 the inclusion of a highphysiological dose of taurine in CNP supplementation (ie, 200 mg) could be beneficial to cancer patients following vegan diets.
Overview
In light of the above discussion, a very provisional design of a CNP for cancer management can now be proposed. The suggested doses are mere estimates; there is no reason to believe that they would provide optimal benefit, albeit it is hoped they would provide some benefit:
• an oil product, configured as soft gels or a flavored emulsion, featuring fish oil enriched in EPA, providing at least 1.5 g EPA per serving; • a powder, for blending into water or juice, featuring, per dose, glycine (8 g), glutamine (8 g), HMB (1 g), MCP (5 g), and a lyophilized probiotic (lactobacillus or bifidobacterium); • a capsule product, featuring, per dose, green tea polyphenols (high in EGCG, 400 mg), silymarin (1 g), mushroom β-glycans (from 1 or more of Agaricus blazei, Ganoderma lucidum, Lentinula edodes; 2 g), policosanol (5 mg), and nattokinase (150 mg);
• and a nutritional insurance formula in tablet formula, featuring all essential or quasi-essential vitamins and minerals save for copper and, in particular, providing per daily dose: selenium (as yeast, 400 µg), β-carotene (25 mg), lycopene (30 mg), vitamin D3 (4000 IU), chromium (as picolinate, 1000 µg), magnesium (500 mg), and taurine (200 mg).
The daily doses of the oil, powder, and capsules are to be taken with meals; the insurance formula can be split between 2 meals daily.
As pharmaceutical adjuvants to this program, TTM 275, 277 and high-dose aspirin, a salicylate salt, or salsalate (∼4.5-6 g daily in multiple divided doses, along with misoprostol, 200 mg twice daily or 3 times daily for GI protection if aspirin is used 328 ) are recommended, under careful physician supervision. Lowdose aspirin, for patients not using high-dose aspirin, can be recommended as an antithrombotic measure. Concurrent administration of low-dose metronomic chemotherapy [329] [330] [331] [332] [333] [334] as well as Gleevec (imatinib) [335] [336] [337] [338] would be expected to amplify the angiostatic efficacy of the regimen. The metronomic chemotherapy-one popular regimen provides 50 mg cyclophosphamide daily and methotrexate 2.5 mg twice daily the first 2 days of each week-is intended to provoke apoptosis of tumor endothelial cells, in part by inducing the angiostatic mediator thrombospondin 1. 332 Topotecan or other topoisomerase I inhibitors may be an especially good choice for metronomic therapy because in tumors that express wild-type topoisomerase I, subcytotoxic concentrations of topotecan can reduce expression of HIF-1α by inhibiting translation of its mRNA. 339, 340 Gleevec (400 to 600 mg daily is the typical regimen used for chronic myeloid leukemia 334 ) is a potent inhibitor of the platelet-derived growth factor receptor and thus can suppress the capacity of tumor endothelium to attract pericytes that promote endothelial cell survival and stabilize nascent tumor capillaries. 335 Also strongly recommended is a low-fat, whole-food vegan diet, in conjunction with regular aerobic exercise. 167, 169, 172 This can be expected to down-regulate systemic IGF-I activity, thereby affecting the capacity of many tumors to proliferate and secrete angiogenic factors. 1 The agents recommended here are all distinguished by the fact that they are orally administrable, are well tolerated when used properly (the tinnitus associated with salicylate being an exception), and are all currently available as nutraceutical ingredients or approved drugs. Thus, this regimen should be feasible for long-term use and can be used now. The only suggested agent that currently is grossly expensive is Gleevec.
It is anticipated-and hoped!-that a program of this type could provide a number of significant benefits for most cancer patients: slowing and perhaps even reversing tumor-evoked angiogenesis, impeding metastasis, amplifying the capacity of NK cells to attack the tumor, reducing risk for thromboembolism, preventing or at least ameliorating cachexia, and slowing bone erosion. In favorable cases, some of the components of this regimen, such as vitamin D, selenium, silymarin, [341] [342] [343] salicylate, and TTM, might exert a direct favorable impact on cancer cells, decreasing their aggressiveness and rendering them more sensitive to cytotoxic therapy. It would be of particular interest to test regimens of this type in nude mice bearing human tumor xenografts, with or without the suggested pharmaceutical adjuvants; the various components could be added to chow or drinking water.
Note that this is proposed as a core nutraceutical program for cancer patients. The use of additional nutraceuticals, or a higher dose of a nutraceutical included in this program, may be warranted in individual cases, either to favorably influence the behavior of a specific type of cancer or to deal with various clinical problems that arise during cancer care. And of course, this program is intended only as an adjuvant to pharmacological, radiological, or surgical measures of proven efficacy that directly attack the cancer.
